Janssen’s Newly Approved Ponvory Joins Crowded MS Space

Ponesimod is the fourth S1P modulator approved to treat multiple sclerosis and joins a sprawling class of oral and injectable therapies. But Janssen sees numerous ways to differentiate its drug.

FDA Approved
Ponvory is the fourth S1P modulator approved to treat MS

Janssen Pharmaceutical Cos. said on 19 March that the US Food and Drug Administration approved Ponvory (ponesimod) for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. The approval brings to market a fourth sphingosine-1-phosphate (S1P) modulator for MS, but the Johnson & Johnson subsidiary thinks it can differentiate its drug against those and a raft of other approved therapies on the basis of selectivity, safety, convenience and rapid reversibility.

Acquired as part of J&J’s 2017 buyout of Actelion Pharmaceuticals Ltd. Ponvory is selective for the S1P receptor 1,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?